Webinars

New Biomarker 14-3-3η: Advances in Diagnosing Early Rheumatoid Arthritis and Differentiating Osteoarthritis

Chapters

Date: Friday, October 10, 2014

Author: Maksymowych, Walter, MD
Scientist, Alberta Heritage Foundation for Medical Research
Consultant Rheumatologist and Professor of Medicine
University of Alberta
Edmonton, Alberta
  
Also by this Author ▸

Category: CE Credit, Webinar

Description: Walter Maksymowych, MD, details the differences between rheumatoid arthritis and osteoarthritis, and discusses the limitation of current markers and the benefits of the 14-3-3η biomarker.

At the conclusion of this program, participants will be able to:
• Differentiate Rheumatoid Arthritis (RA) from Osteoarthritis (OA)
• Understand the major limitations of current markers RF and anti-CCP antibody
• Learn how 14-3-3eta can help overcome the seronegativity of RF and anti-CCP antibody in early and established RA
ASCLS P.A.C.E.® credits available to laboratory professionals through April 6, 2015.

Evaluation survey and P.A.C.E. credit

Related Content

Presentation:
Advanced Insights into Residual Cardiovascular Risk-Another Perspective
Levenson, Ian, DO, FACOFP, Lipidologist

Presentation:
14-3-3 eta Protein: A New Direction in the Early Diagnosis of Rheumatoid Arthritis
Maksymowych, Walter, MD

Expert Insight:
14-3-3eta (η) Protein — A New Biomarker for Rheumatoid Arthritis
Maksymowych, Walter, MD